Novo Nordisk has released positive results from a new phase three trial of its PBS-listed diabetes medicine OZEPMPIC (semaglutide) confirming its potential as a treatment for weight loss. …
Novo Nordisk's PBS-listed GLP-1 agonist in weight loss 'game-changer'
February 15, 2021 BioPharmaLatest News
Latest Video
New Stories
-
Is there any example of another review or inquiry taking this long?
April 10, 2026 - - Latest News -
Rewriting the rules of PBS negotiations to deliver a patient-first reset
April 10, 2026 - - Latest News -
A decade of readiness as AVITA medical expands burn response capability
April 9, 2026 - - Australian Biotech -
Moderna names Carolyn Tucek-Szabo to lead Australia and New Zealand operations
April 9, 2026 - - Latest News -
New Zealand's Pharmac announces a shift in treatment for blood cancer
April 9, 2026 - - Latest News -
It is imperative to very carefully read what the minister said, and then read it again
April 9, 2026 - - Latest News -
Stuart Dignam joins MTPConnect board as it embarks on its second decade
April 8, 2026 - - Latest News